Acute onset ocular myasthenia gravis after vaccination with the Oxford-AstraZeneca COVID-19 vaccine
Dominic I. Maher, Daniel T. Hogarty, Elad Ben Artsi
Abstract
Myasthenia gravis (MG) is an autoimmune disease that results in muscle weakness and fatigability. Extraocular involvement may be the first sign of disease. It may be triggered by infections, stress, or medications. We describe a first reported case of ocular MG induced by the viral vector Oxford-AstraZeneca coronavirus disease (COVID-19) vaccine, detail the pathophysiology of vaccine-induced MG, and explore the impact of COVID-19 on MG patients.
Topics & Concepts
MedicineMyasthenia gravisCoronavirus disease 2019 (COVID-19)Extraocular musclesPathophysiologyOcular myastheniaVaccinationSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakDiseaseMuscle weaknessWeaknessImmunologyVirologyOphthalmologyInternal medicineSurgeryInfectious disease (medical specialty)OutbreakMyasthenia Gravis and ThymomaPeripheral Neuropathies and DisordersAntifungal resistance and susceptibility